Paratek's omadacycline meets Phase III endpoints

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) jumped $4.07 (25%) to $20.51 in early after-hours trading after its omadacycline (formerly PTK 0796) met FDA- and EMA-specified

Read the full 232 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE